6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
:	:	:	:	:	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	I-Severity
severe	JJ	severe	severe	sever	N	I-Severity
intensity	NN	intensity	intensity	intens	N	O
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
are	VBP	are	are	are	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Janssen	NNP	janssen	janssen	janssen	N	O
Products	NNP	products	product	product	N	O
,	,	,	,	,	N	O
LP	NNP	lp	lp	lp	Y	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
JANSSEN	NNP	janssen	janssen	janssen	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
526	CD	526	526	526	N	O
-	:	-	-	-	N	O
7736	CD	7736	7736	7736	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
:	:	:	:	:	N	O
Adults	NNS	adults	adult	adult	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
assessment	NN	assessment	assessment	assess	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
all	DT	all	all	all	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
1203	CD	1203	1203	1203	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C206	NN	c206	c206	c206	N	O
and	CC	and	and	and	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C216	NN	c216	c216	c216	N	O
,	,	,	,	,	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
599	CD	599	599	599	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
received	VBD	received	received	receiv	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
200	CD	200	200	200	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
pooled	JJ	pooled	pooled	pool	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
exposure	NN	exposure	exposure	exposur	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
was	VBD	was	wa	wa	N	O
52.3	CD	52.3	52.3	52.3	N	O
and	CC	and	and	and	N	O
51.0	CD	51.0	51.0	51.0	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
ADRs	NNP	adrs	adrs	adr	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
5.2%	CD	5.2%	5.2%	5.2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
ADR	NNP	adr	adr	adr	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
Grade	$	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
was	VBD	was	wa	wa	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
10.0%	CD	10.0%	10.0%	10.0%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	O
and	CC	and	and	and	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
during	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
with	IN	with	with	with	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
of	IN	of	of	of	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	JJ	infected	infected	infect	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
rash	VB	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
general	JJ	general	general	gener	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
mild	VBN	mild	mild	mild	N	B-Severity
to	TO	to	to	to	N	I-Severity
moderate	VB	moderate	moderate	moder	N	I-Severity
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
primarily	RB	primarily	primarily	primarili	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
week	NN	week	week	week	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
after	IN	after	after	after	N	O
Week	JJ	week	week	week	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
generally	RB	generally	generally	gener	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
on	IN	on	on	on	N	O
continued	JJ	continued	continued	continu	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
women	NNS	women	woman	women	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
men	NNS	men	men	men	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
9	CD	9	9	9	N	O
60	CD	60	60	60	N	O
[	JJ	[	[	[	N	O
15.0%	CD	15.0%	15.0%	15.0%	N	O
]	JJ	]	]	]	N	O
women	NNS	women	woman	women	N	O
versus	VBD	versus	versus	versu	N	O
51	CD	51	51	51	N	O
539	CD	539	539	539	N	O
[	JJ	[	[	[	N	O
9.5%	CD	9.5%	9.5%	9.5%	N	O
]	JJ	]	]	]	N	O
men	NNS	men	men	men	N	O
;	:	;	;	;	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
rash	VB	rash	rash	rash	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
60	CD	60	60	60	N	O
[	JJ	[	[	[	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
]	JJ	]	]	]	N	O
women	NNS	women	woman	women	N	O
versus	VBD	versus	versus	versu	N	O
10	CD	10	10	10	N	O
539	CD	539	539	539	N	O
[	JJ	[	[	[	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
]	JJ	]	]	]	N	O
men	NNS	men	men	men	N	O
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
NNRTI	NNP	nnrti	nnrti	nnrti	N	B-DrugClass
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
appear	VB	appear	appear	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
without	IN	without	without	without	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
NNRTI	NNP	nnrti	nnrti	nnrti	N	B-DrugClass
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
ADRs	NNP	adrs	adrs	adr	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	O
intensity	NN	intensity	intensity	intens	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
excess	NN	excess	excess	excess	N	O
of	IN	of	of	of	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
considered	VBN	considered	considered	consid	N	O
ADRs	NNP	adrs	adrs	adr	N	O
are	VBP	are	are	are	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
Table	NNP	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Emergent	JJ	emergent	emergent	emerg	N	O
Adverse	NNP	adverse	adverse	advers	N	O
ReactionsIncludes	NNP	reactionsincludes	reactionsincludes	reactionsinclud	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
possibly	RB	possibly	possibly	possibl	N	O
,	,	,	,	,	N	O
probably	RB	probably	probably	probabl	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
very	RB	very	very	veri	N	O
likely	RB	likely	likely	like	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
Moderate	JJ	moderate	moderate	moder	N	O
IntensityIntensities	NNS	intensityintensities	intensityintensities	intensityintens	N	O
are	VBP	are	are	are	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
follows	VBZ	follows	follows	follow	N	O
:	:	:	:	:	N	O
Moderate	NNP	moderate	moderate	moder	N	O
(	(	(	(	(	N	O
discomfort	VB	discomfort	discomfort	discomfort	Y	O
enough	RB	enough	enough	enough	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
interference	NN	interference	interference	interfer	N	O
with	IN	with	with	with	N	O
usual	JJ	usual	usual	usual	N	O
activity	NN	activity	activity	activ	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
incapacitating	VBG	incapacitating	incapacitating	incapacit	N	O
with	IN	with	with	with	N	O
inability	NN	inability	inability	inabl	N	O
to	TO	to	to	to	N	O
work	VB	work	work	work	N	O
or	CC	or	or	or	N	O
do	VB	do	do	do	N	O
usual	JJ	usual	usual	usual	N	O
activity	NN	activity	activity	activ	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
Grades	VBZ	grades	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
Adult	NNP	adult	adult	adult	N	O
Subjects	NNP	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
Treatment	NN	treatment	treatment	treatment	N	O
Groups	NNP	groups	group	group	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
excess	NN	excess	excess	excess	N	O
of	IN	of	of	of	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
,	,	,	,	,	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
,	,	,	,	,	N	O
Pooled	NNP	pooled	pooled	pool	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C206	NN	c206	c206	c206	N	O
and	CC	and	and	and	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C216	NN	c216	c216	c216	N	O
Trials	NNS	trials	trial	trial	N	O

INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
BRN	NNP	brn	brn	brn	N	O
599	CD	599	599	599	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
BRN	NNP	brn	brn	brn	N	O
604	CD	604	604	604	N	O

N	NN	n	n	n	N	O

total	JJ	total	total	total	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
per	IN	per	per	per	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
BR	NNP	br	br	br	Y	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O

System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	VBD	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
4%	CD	4%	4%	4%	N	O
2%	CD	2%	2%	2%	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
10%	CD	10%	10%	10%	N	O
3%	CD	3%	3%	3%	N	O

Less	NNP	less	le	less	N	O
Common	NNP	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Treatment	NN	treatment	treatment	treatment	N	O

-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
ADRs	NNP	adrs	adrs	adr	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
599	CD	599	599	599	N	O
subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
moderate	JJ	moderate	moderate	moder	N	O
intensity	NN	intensity	intensity	intens	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
below	IN	below	below	below	N	O
by	IN	by	by	by	N	O
body	NN	body	body	bodi	N	O
system	NN	system	system	system	N	O
:	:	:	:	:	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
angina	JJ	angina	angina	angina	N	B-AdverseReaction
pectoris	NN	pectoris	pectoris	pectori	N	I-AdverseReaction
,	,	,	,	,	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
Labyrinth	JJ	labyrinth	labyrinth	labyrinth	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
gastroesophageal	NN	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastritis	NN	gastritis	gastritis	gastriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
distension	NN	distension	distension	distens	N	I-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
hematemesis	NN	hematemesis	hematemesis	hematemesi	Y	B-AdverseReaction
,	,	,	,	,	N	O
retching	VBG	retching	retching	retch	Y	B-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
sluggishness	NN	sluggishness	sluggishness	sluggish	Y	B-AdverseReaction

Hematologic	JJ	hematologic	hematologic	hematolog	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hemolytic	JJ	hemolytic	hemolytic	hemolyt	N	B-AdverseReaction
anemia	NN	anemia	anemia	anemia	Y	I-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatomegaly	NN	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
,	,	,	,	,	N	O
cytolytic	JJ	cytolytic	cytolytic	cytolyt	N	B-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
,	,	,	,	,	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
steatosis	NN	steatosis	steatosis	steatosi	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
,	,	,	,	,	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	B-AdverseReaction
mellitus	VBP	mellitus	mellitus	mellitu	N	I-AdverseReaction
,	,	,	,	,	N	O
anorexia	UH	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
paraesthesia	NN	paraesthesia	paraesthesia	paraesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
convulsion	NN	convulsion	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
amnesia	NN	amnesia	amnesia	amnesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
,	,	,	,	,	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
,	,	,	,	,	N	O
hypersomnia	NN	hypersomnia	hypersomnia	hypersomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
,	,	,	,	,	N	O
sleep	JJ	sleep	sleep	sleep	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
dreams	NNS	dreams	dream	dream	N	I-AdverseReaction
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
disorientation	NN	disorientation	disorientation	disorient	Y	B-AdverseReaction
,	,	,	,	,	N	O
nervousness	NN	nervousness	nervousness	nervous	Y	B-AdverseReaction
,	,	,	,	,	N	O
nightmares	NNS	nightmares	nightmare	nightmar	Y	B-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
System	NNP	system	system	system	N	O
and	CC	and	and	and	N	O
Breast	NNP	breast	breast	breast	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
exertional	JJ	exertional	exertional	exert	N	B-AdverseReaction
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	I-AdverseReaction
,	,	,	,	,	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
night	NN	night	night	night	N	B-AdverseReaction
sweats	NNS	sweats	sweat	sweat	N	I-AdverseReaction
,	,	,	,	,	N	O
lipohypertrophy	NN	lipohypertrophy	lipohypertrophy	lipohypertrophi	Y	B-AdverseReaction
,	,	,	,	,	N	O
prurigo	NN	prurigo	prurigo	prurigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
,	,	,	,	,	N	O
swelling	VBG	swelling	swelling	swell	Y	B-AdverseReaction
face	NN	face	face	face	N	I-AdverseReaction

Additional	NNP	additional	additional	addit	N	O
ADRs	NNP	adrs	adrs	adr	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
moderate	JJ	moderate	moderate	moder	N	O
intensity	NN	intensity	intensity	intens	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
acquired	VBN	acquired	acquired	acquir	N	B-AdverseReaction
lipodystrophy	NN	lipodystrophy	lipodystrophy	lipodystrophi	Y	I-AdverseReaction
,	,	,	,	,	N	O
angioneurotic	JJ	angioneurotic	angioneurotic	angioneurot	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
and	CC	and	and	and	N	O
haemorrhagic	JJ	haemorrhagic	haemorrhagic	haemorrhag	N	B-AdverseReaction
stroke	NN	stroke	stroke	stroke	Y	I-AdverseReaction
,	,	,	,	,	N	O
each	DT	each	each	each	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
no	DT	no	no	no	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Experienced	VBD	experienced	experienced	experienc	N	O
Patients	NNS	patients	patient	patient	N	O

Selected	VBN	selected	selected	select	N	O
Grade	VBD	grade	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
that	WDT	that	that	that	N	O
represent	VBP	represent	represent	repres	N	O
a	DT	a	a	a	N	O
worsening	NN	worsening	worsening	worsen	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Selected	VBN	selected	selected	select	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNPS	abnormalities	abnormality	abnorm	N	O
Observed	NNP	observed	observed	observ	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
Experienced	JJ	experienced	experienced	experienc	N	O
Subjects	NNS	subjects	subject	subject	N	O

Pooled	VBN	pooled	pooled	pool	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C206	NN	c206	c206	c206	N	O
and	CC	and	and	and	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C216	NN	c216	c216	c216	N	O
Trials	NNS	trials	trial	trial	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
ParameterPreferred	NNP	parameterpreferred	parameterpreferred	parameterpref	N	O
Term	NNP	term	term	term	N	O
,	,	,	,	,	N	O
DAIDS	NNP	daids	daids	daid	N	O
Toxicity	NNP	toxicity	toxicity	toxic	N	O
Range	NNP	range	range	rang	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
BRN	NNP	brn	brn	brn	N	O
599	CD	599	599	599	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
BRN	NNP	brn	brn	brn	N	O
604	CD	604	604	604	N	O

ULN	NN	uln	uln	uln	N	O

Upper	NNP	upper	upper	upper	N	O
Limit	NNP	limit	limit	limit	N	O
of	IN	of	of	of	N	O
Normal	NNP	normal	normal	normal	N	O
,	,	,	,	,	N	O
BR	NNP	br	br	br	Y	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O

GENERAL	NNP	general	general	gener	N	O

BIOCHEMISTRY	NN	biochemistry	biochemistry	biochemistri	N	O

Pancreatic	JJ	pancreatic	pancreatic	pancreat	N	O
amylase	NN	amylase	amylase	amylas	Y	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
1.5	CD	1.5	1.5	1.5	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
ULN	NNP	uln	uln	uln	N	O
7%	CD	7%	7%	7%	N	O
8%	CD	8%	8%	8%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
7%	CD	7%	7%	7%	N	O
8%	CD	8%	8%	8%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O

Lipase	NN	lipase	lipase	lipas	Y	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
1.5	CD	1.5	1.5	1.5	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
ULN	NNP	uln	uln	uln	N	O
4%	CD	4%	4%	4%	N	O
6%	CD	6%	6%	6%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

Creatinine	NN	creatinine	creatinine	creatinin	Y	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
1.4	CD	1.4	1.4	1.4	N	O
-	:	-	-	-	N	O
1.8	CD	1.8	1.8	1.8	N	O
ULN	NNP	uln	uln	uln	N	O
6%	CD	6%	6%	6%	N	O
5%	CD	5%	5%	5%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
1.9	CD	1.9	1.9	1.9	N	O
-	:	-	-	-	N	O
3.4	CD	3.4	3.4	3.4	N	O
ULN	NNP	uln	uln	uln	N	O
2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
3.4	CD	3.4	3.4	3.4	N	O
ULN	NNP	uln	uln	uln	N	O
0%	CD	0%	0%	0%	N	O
1%	CD	1%	1%	1%	N	O

HEMATOLOGY	NN	hematology	hematology	hematolog	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
90	CD	90	90	90	N	O
-	:	-	-	-	N	O
99	CD	99	99	99	N	O
g	NN	g	g	g	N	O
L	NNP	l	l	l	N	O
2%	CD	2%	2%	2%	N	O
4%	CD	4%	4%	4%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
70	CD	70	70	70	N	O
-	:	-	-	-	N	O
89	CD	89	89	89	N	O
g	NN	g	g	g	N	O
L	NNP	l	l	l	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
70	CD	70	70	70	N	O
g	NN	g	g	g	N	O
L	NNP	l	l	l	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

White	NNP	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
count	NN	count	count	count	N	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
500	CD	500	500	500	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
999	CD	999	999	999	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
2%	CD	2%	2%	2%	N	O
3%	CD	3%	3%	3%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
499	CD	499	499	499	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
1%	CD	1%	1%	1%	N	O
4%	CD	4%	4%	4%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
750	CD	750	750	750	N	O
-	:	-	-	-	N	O
999	CD	999	999	999	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
5%	CD	5%	5%	5%	N	O
6%	CD	6%	6%	6%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
500	CD	500	500	500	N	O
-	:	-	-	-	N	O
749	CD	749	749	749	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
4%	CD	4%	4%	4%	N	O
4%	CD	4%	4%	4%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
500	CD	500	500	500	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
2%	CD	2%	2%	2%	N	O
3%	CD	3%	3%	3%	N	O

Platelet	NNP	platelet	platelet	platelet	N	O
count	NN	count	count	count	N	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
50	CD	50	50	50	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
-	:	-	-	-	N	O
99	CD	99	99	99	N	O
,	,	,	,	,	N	O
999	CD	999	999	999	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
3%	CD	3%	3%	3%	N	O
5%	CD	5%	5%	5%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
-	:	-	-	-	N	O
49	CD	49	49	49	N	O
,	,	,	,	,	N	O
999	CD	999	999	999	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
25	CD	25	25	25	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

LIPIDS	NNP	lipids	lipid	lipid	Y	O
AND	CC	and	and	and	N	O
GLUCOSE	NNP	glucose	glucose	glucos	Y	O

Total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
6.20	CD	6.20	6.20	6.20	N	O
-	:	-	-	-	N	O
7.77	CD	7.77	7.77	7.77	N	O
mmol	NN	mmol	mmol	mmol	N	O
L240	NNP	l240	l240	l240	N	O
-	:	-	-	-	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
20%	CD	20%	20%	20%	N	O
17%	CD	17%	17%	17%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
7.77	CD	7.77	7.77	7.77	N	O
mmol	NN	mmol	mmol	mmol	N	O
L	NNP	l	l	l	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
8%	CD	8%	8%	8%	N	O
5%	CD	5%	5%	5%	N	O

Low	JJ	low	low	low	N	O
density	NN	density	density	densiti	N	O
lipoprotein	NN	lipoprotein	lipoprotein	lipoprotein	N	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
4.13	CD	4.13	4.13	4.13	N	O
-	:	-	-	-	N	O
4.9	CD	4.9	4.9	4.9	N	O
mmol	NN	mmol	mmol	mmol	N	O
L160	NNP	l160	l160	l160	N	O
-	:	-	-	-	N	O
190	CD	190	190	190	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
13%	CD	13%	13%	13%	N	O
12%	CD	12%	12%	12%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4.9	CD	4.9	4.9	4.9	N	O
mmol	NN	mmol	mmol	mmol	N	O
L	NNP	l	l	l	N	O
190	CD	190	190	190	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
7%	CD	7%	7%	7%	N	O
7%	CD	7%	7%	7%	N	O

Triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
5.65	CD	5.65	5.65	5.65	N	O
-	:	-	-	-	N	O
8.48	CD	8.48	8.48	8.48	N	O
mmol	NN	mmol	mmol	mmol	N	O
L500	NNP	l500	l500	l500	N	O
-	:	-	-	-	N	O
750	CD	750	750	750	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
9%	CD	9%	9%	9%	N	O
7%	CD	7%	7%	7%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
8.49	CD	8.49	8.49	8.49	N	O
-	:	-	-	-	N	O
13.56	CD	13.56	13.56	13.56	N	O
mmol	NN	mmol	mmol	mmol	N	O
L751	NNP	l751	l751	l751	N	O
-	:	-	-	-	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
6%	CD	6%	6%	6%	N	O
4%	CD	4%	4%	4%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
13.56	CD	13.56	13.56	13.56	N	O
mmol	NN	mmol	mmol	mmol	N	O
L	NNP	l	l	l	N	O
1200	CD	1200	1200	1200	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
4%	CD	4%	4%	4%	N	O
2%	CD	2%	2%	2%	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
6.95	CD	6.95	6.95	6.95	N	O
-	:	-	-	-	N	O
13.88	CD	13.88	13.88	13.88	N	O
mmol	NN	mmol	mmol	mmol	N	O
L161	NNP	l161	l161	l161	N	O
-	:	-	-	-	N	O
250	CD	250	250	250	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
15%	CD	15%	15%	15%	N	O
13%	CD	13%	13%	13%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
13.89	CD	13.89	13.89	13.89	N	O
-	:	-	-	-	N	O
27.75	CD	27.75	27.75	27.75	N	O
mmol	NN	mmol	mmol	mmol	N	O
L251	NNP	l251	l251	l251	N	O
-	:	-	-	-	N	O
500	CD	500	500	500	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
4%	CD	4%	4%	4%	N	O
2%	CD	2%	2%	2%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
27.75	CD	27.75	27.75	27.75	N	O
mmol	NN	mmol	mmol	mmol	N	O
L	NNP	l	l	l	N	O
500	CD	500	500	500	N	O
mg	NN	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
0%	CD	0%	0%	0%	N	O
1%	CD	1%	1%	1%	N	O

HEPATIC	NNP	hepatic	hepatic	hepat	N	O
PARAMETERS	NNS	parameters	parameter	paramet	N	O

Alanine	NNP	alanine	alanine	alanin	N	O
amino	NN	amino	amino	amino	N	O
transferase	NN	transferase	transferase	transferas	N	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
2.6	CD	2.6	2.6	2.6	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
6%	CD	6%	6%	6%	N	O
5%	CD	5%	5%	5%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
5.1	CD	5.1	5.1	5.1	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
ULN	NNP	uln	uln	uln	N	O
3%	CD	3%	3%	3%	N	O
2%	CD	2%	2%	2%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
10	CD	10	10	10	N	O
ULN	NNP	uln	uln	uln	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	O
amino	NN	amino	amino	amino	N	O
transferase	NN	transferase	transferase	transferas	N	O

Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
2.6	CD	2.6	2.6	2.6	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
6%	CD	6%	6%	6%	N	O
8%	CD	8%	8%	8%	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
5.1	CD	5.1	5.1	5.1	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
ULN	NNP	uln	uln	uln	N	O
3%	CD	3%	3%	3%	N	O
2%	CD	2%	2%	2%	N	O

Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
10	CD	10	10	10	N	O
ULN	NNP	uln	uln	uln	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

Patients	NNS	patients	patient	patient	N	O
co	VBP	co	co	co	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hepatitis	VB	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
virus	NN	virus	virus	viru	N	O

In	IN	in	in	in	N	O

Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C206	NN	c206	c206	c206	N	O
and	CC	and	and	and	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C216	NNP	c216	c216	c216	N	O
,	,	,	,	,	N	O
139	CD	139	139	139	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
12.3%	CD	12.3%	12.3%	12.3%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hepatitis	VB	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
virus	NN	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
1129	CD	1129	1129	1129	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
permitted	VBN	permitted	permitted	permit	N	O
to	TO	to	to	to	N	O
enroll	VB	enroll	enroll	enrol	N	O
.	.	.	.	.	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hepatitis	VB	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
virus	NN	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infected	JJ	infected	infected	infect	N	O
subjects	NNS	subjects	subject	subject	N	O
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	B-AdverseReaction
that	WDT	that	that	that	N	O
represent	VBP	represent	represent	repres	N	O
a	DT	a	a	a	N	O
worsening	NN	worsening	worsening	worsen	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	I-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
or	CC	or	or	or	N	O
total	JJ	total	total	total	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
27.8%	CD	27.8%	27.8%	27.8%	N	O
,	,	,	,	,	N	O
25.0%	CD	25.0%	25.0%	25.0%	N	O
and	CC	and	and	and	N	O
7.1%	CD	7.1%	7.1%	7.1%	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infected	JJ	infected	infected	infect	N	O
subjects	NNS	subjects	subject	subject	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
6.7%	CD	6.7%	6.7%	6.7%	N	O
,	,	,	,	,	N	O
7.5%	CD	7.5%	7.5%	7.5%	N	O
and	CC	and	and	and	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
co	NN	co	co	co	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
general	JJ	general	general	gener	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hepatitis	VB	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
virus	NN	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
without	IN	without	without	without	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hepatitis	VB	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
virus	NN	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
:	:	:	:	:	N	O
Pediatric	JJ	pediatric	pediatric	pediatr	N	O
Subjects	NNP	subjects	subject	subject	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
assessment	NN	assessment	assessment	assess	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
and	CC	and	and	and	N	O
adolescents	NNS	adolescents	adolescent	adolesc	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
Week	NNP	week	week	week	N	O
24	CD	24	24	24	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
,	,	,	,	,	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
trial	NN	trial	trial	trial	N	O
TMC125	NNP	tmc125	tmc125	tmc125	N	O
-	:	-	-	-	N	O
C213	NN	c213	c213	c213	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
101	CD	101	101	101	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
infected	JJ	infected	infected	infect	N	O
subjects	NNS	subjects	subject	subject	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
weighing	VBG	weighing	weighing	weigh	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
16	CD	16	16	16	N	O
kg	NNS	kg	kg	kg	N	O
received	VBN	received	received	receiv	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
agents	NNS	agents	agent	agent	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
,	,	,	,	,	N	O
type	NN	type	type	type	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
except	IN	except	except	except	N	O
for	IN	for	for	for	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
which	WDT	which	which	which	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Rash	NN	rash	rash	rash	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
subjects	NNS	subjects	subject	subject	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
male	JJ	male	male	male	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
13	CD	13	13	13	N	O
64	CD	64	64	64	N	O
[	JJ	[	[	[	N	O
20.3%	CD	20.3%	20.3%	20.3%	N	O
]	JJ	]	]	]	N	O
females	NNS	females	female	femal	N	O
versus	VBP	versus	versus	versu	N	O
2	CD	2	2	2	N	O
37	CD	37	37	37	N	O
[	JJ	[	[	[	N	O
5.4%	CD	5.4%	5.4%	5.4%	N	O
]	JJ	]	]	]	N	O
males	NNS	males	male	male	N	O
;	:	;	;	;	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
rash	VB	rash	rash	rash	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
64	CD	64	64	64	N	O
[	JJ	[	[	[	N	O
6.3%	CD	6.3%	6.3%	6.3%	N	O
]	JJ	]	]	]	N	O
females	NNS	females	female	femal	N	O
versus	VBP	versus	versus	versu	N	O
0	CD	0	0	0	N	O
37	CD	37	37	37	N	O
[	JJ	[	[	[	N	O
0%	CD	0%	0%	0%	N	O
]	JJ	]	]	]	N	O
males	NNS	males	male	male	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
mild	VBN	mild	mild	mild	N	B-Severity
to	TO	to	to	to	N	I-Severity
moderate	VB	moderate	moderate	moder	N	I-Severity
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
macular	JJ	macular	macular	macular	N	I-AdverseReaction
papular	JJ	papular	papular	papular	N	I-AdverseReaction
type	NN	type	type	type	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
week	NN	week	week	week	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
self	VBN	self	self	self	N	O
-	:	-	-	-	N	O
limiting	NN	limiting	limiting	limit	N	O
and	CC	and	and	and	N	O
generally	RB	generally	generally	gener	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
on	IN	on	on	on	N	O
continued	JJ	continued	continued	continu	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
completed	VBD	completed	completed	complet	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
completed	VBD	completed	completed	complet	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
unknown	JJ	unknown	unknown	unknown	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
including	VBG	including	including	includ	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
and	CC	and	and	and	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
rhabdomyolysis	NN	rhabdomyolysis	rhabdomyolysis	rhabdomyolysi	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
potentially	RB	potentially	potentially	potenti	N	O
life	NN	life	life	life	N	B-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
includes	VBZ	includes	includes	includ	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
and	CC	and	and	and	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
.	.	.	.	.	N	O

Immediately	RB	immediately	immediately	immedi	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	O
rash	NN	rash	rash	rash	Y	O
or	CC	or	or	or	N	O
rash	NN	rash	rash	rash	Y	O
with	IN	with	with	with	N	O
systemic	JJ	systemic	systemic	system	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
liver	JJ	liver	liver	liver	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
develops	NNS	develops	develops	develop	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
clinical	JJ	clinical	clinical	clinic	N	O
status	NN	status	status	statu	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
liver	NN	liver	liver	liver	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Severe	JJ	severe	severe	sever	N	O
Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
potentially	RB	potentially	potentially	potenti	N	B-Factor
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
include	VBP	include	include	includ	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
and	CC	and	and	and	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
Drug	NNP	drug	drug	drug	N	B-AdverseReaction
Rash	NNP	rash	rash	rash	Y	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
Eosinophilia	NNP	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
Systemic	NNP	systemic	systemic	system	N	I-AdverseReaction
Symptoms	NNP	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
characterized	VBN	characterized	characterized	character	N	O
by	IN	by	by	by	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
constitutional	JJ	constitutional	constitutional	constitut	N	O
findings	NNS	findings	finding	find	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
organ	JJ	organ	organ	organ	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
and	CC	and	and	and	N	O
4	CD	4	4	4	N	I-Severity
rashes	NNS	rashes	rash	rash	N	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
of	IN	of	of	of	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	JJ	infected	infected	infect	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
rash	VB	rash	rash	rash	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
most	JJS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
females	NNS	females	female	femal	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
immediately	RB	immediately	immediately	immedi	N	O
if	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
skin	JJ	skin	skin	skin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
or	CC	or	or	or	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
develop	VBP	develop	develop	develop	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	O
rash	NN	rash	rash	rash	Y	O
or	CC	or	or	or	N	O
rash	NN	rash	rash	rash	Y	O
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
general	JJ	general	general	gener	N	O
malaise	NN	malaise	malaise	malais	Y	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	O
or	CC	or	or	or	N	O
joint	JJ	joint	joint	joint	N	O
aches	NNS	aches	ache	ach	N	O
,	,	,	,	,	N	O
blisters	NNS	blisters	blister	blister	Y	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
lesions	NNS	lesions	lesion	lesion	N	O
,	,	,	,	,	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	O
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	O
edema	NN	edema	edema	edema	Y	O
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
,	,	,	,	,	N	O
eosinophilia	NN	eosinophilia	eosinophilia	eosinophilia	Y	O
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
status	NN	status	status	statu	N	O
including	VBG	including	including	includ	N	O
liver	NN	liver	liver	liver	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
initiated	VBN	initiated	initiated	initi	N	O
.	.	.	.	.	N	O

Delay	NN	delay	delay	delay	N	O
in	IN	in	in	in	N	O
stopping	VBG	stopping	stopping	stop	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
rash	NN	rash	rash	rash	Y	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Fat	NNP	fat	fat	fat	N	O
Redistribution	NNP	redistribution	redistribution	redistribut	N	O

Redistribution	NNP	redistribution	redistribution	redistribut	N	B-AdverseReaction
accumulation	NN	accumulation	accumulation	accumul	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
fat	JJ	fat	fat	fat	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
central	JJ	central	central	central	N	B-AdverseReaction
obesity	NN	obesity	obesity	obes	Y	I-AdverseReaction
,	,	,	,	,	N	O
dorsocervical	JJ	dorsocervical	dorsocervical	dorsocerv	N	B-AdverseReaction
fat	NN	fat	fat	fat	N	I-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
(	(	(	(	(	N	O
buffalo	JJ	buffalo	buffalo	buffalo	N	B-AdverseReaction
hump	NN	hump	hump	hump	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
wasting	NN	wasting	wasting	wast	Y	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
wasting	NN	wasting	wasting	wast	Y	I-AdverseReaction
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
"	NNP	"	"	"	N	O
cushingoid	VBP	cushingoid	cushingoid	cushingoid	Y	B-AdverseReaction
appearance	NN	appearance	appearance	appear	N	I-AdverseReaction
"	NNS	"	"	"	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
and	CC	and	and	and	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
currently	RB	currently	currently	current	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Immune	NNP	immune	immune	immun	N	O
Reconstitution	NNP	reconstitution	reconstitution	reconstitut	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
combination	NN	combination	combination	combin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	B-DrugClass
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
INTELENCE	NNP	intelence	intelence	intel	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
combination	NN	combination	combination	combin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
immune	JJ	immune	immune	immun	N	O
system	NN	system	system	system	N	O
responds	NNS	responds	responds	respond	N	O
may	MD	may	may	may	N	O
develop	VB	develop	develop	develop	N	O
an	DT	an	an	an	N	O
inflammatory	JJ	inflammatory	inflammatory	inflammatori	N	B-AdverseReaction
response	NN	response	response	respons	N	I-AdverseReaction
to	TO	to	to	to	N	O
indolent	NN	indolent	indolent	indol	N	O
or	CC	or	or	or	N	O
residual	JJ	residual	residual	residu	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Mycobacterium	NNP	mycobacterium	mycobacterium	mycobacterium	N	B-AdverseReaction
avium	NN	avium	avium	avium	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
cytomegalovirus	NN	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	B-AdverseReaction
,	,	,	,	,	N	O
Pneumocystis	NNP	pneumocystis	pneumocystis	pneumocysti	N	B-AdverseReaction
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
(	(	(	(	(	N	O
PCP	NNP	pcp	pcp	pcp	N	B-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
necessitate	VB	necessitate	necessitate	necessit	N	O
further	JJ	further	further	further	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Autoimmune	NNP	autoimmune	autoimmune	autoimmun	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Graves	NNS	graves	graf	grave	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
polymyositis	NN	polymyositis	polymyositis	polymyos	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
immune	JJ	immune	immune	immun	N	O
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
is	VBZ	is	is	is	N	O
more	RBR	more	more	more	N	O
variable	JJ	variable	variable	variabl	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
many	JJ	many	many	mani	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

